Clinical Competition Candidate
ZYCLARA
ZYCLARA carries use-code patent, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 41 months away. Active clinical competition may compress the generic entry window.
LOE window
41months
to latest listed patent expiry (December 11, 2029)
Expiry attractiveness: 4/5
Patent profile
Substance patent (none)
Product / formulation patent (none)
Use-code patent (listed)
Patent count: 2
Complexity score: 1/5
Clinical competition
Score: 5/5
Active trials linked: 224
Phase 2/3 trials: 91
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: IMIQUIMOD
Applicant (NDA holder): BAUSCH HEALTH US LLC
Confidence: High